$GILD Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in GILEAD SCIENCES INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in GILEAD SCIENCES INC. Get notifications about new insider transactions in GILEAD SCIENCES INC for free.
Page: < prev 1 ... 8 9 10 11 12 13 14 15 16 ... 46 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 23.76 | 4,800 | 114,024 | 4,800 | |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 19.09 | 11,550 | 220,432 | 11,550 | |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 112.24 | 1,700 | 190,814 | 49,832 | 51.5 K to 49.8 K (-3.30 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 111.69 | 2,775 | 309,936 | 51,532 | 54.3 K to 51.5 K (-5.11 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 110.15 | 21,435 | 2,361,057 | 54,307 | 75.7 K to 54.3 K (-28.30 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 109.59 | 7,282 | 798,030 | 75,742 | 83 K to 75.7 K (-8.77 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 40.56 | 5,592 | 226,812 | 83,024 | 77.4 K to 83 K (+7.22 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 24.30 | 11,250 | 273,319 | 77,432 | 66.2 K to 77.4 K (+17.00 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 23.76 | 4,800 | 114,024 | 66,182 | 61.4 K to 66.2 K (+7.82 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 19.09 | 11,550 | 220,432 | 61,382 | 49.8 K to 61.4 K (+23.18 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 8.01 | 140,625 | 1,125,703 | 140,633 | |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 112.42 | 9,025 | 1,014,617 | 4,429,387 | 4.4 M to 4.4 M (-0.20 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 111.83 | 20,400 | 2,281,405 | 4,438,412 | 4.5 M to 4.4 M (-0.46 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 110.17 | 55,454 | 6,109,190 | 4,458,812 | 4.5 M to 4.5 M (-1.23 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 109.78 | 55,746 | 6,119,891 | 4,514,266 | 4.6 M to 4.5 M (-1.22 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 8.01 | 140,625 | 1,125,703 | 4,570,012 | 4.4 M to 4.6 M (+3.17 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 0.00 | 4,800 | 0 | 12,500 | |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 40.56 | 3,000 | 121,680 | 21,240 | |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Payment of Exercise | F | 109.72 | 2,736 | 300,194 | 34,308 | 31.6 K to 34.3 K (+8.67 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 0.00 | 4,800 | 0 | 37,044 | 32.2 K to 37 K (+14.89 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 112.46 | 3,000 | 337,380 | 32,244 | 35.2 K to 32.2 K (-8.51 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 40.56 | 3,000 | 121,680 | 35,244 | 32.2 K to 35.2 K (+9.30 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | M | 26.99 | 5,000 | 134,950 | 20,000 | |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 112.02 | 5,000 | 560,090 | 15,641 | 20.6 K to 15.6 K (-24.22 %) |
| Nov 05 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Buy | M | 26.99 | 5,000 | 134,950 | 20,641 | 15.6 K to 20.6 K (+31.97 %) |
| Oct 28 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 40.56 | 2,000 | 81,120 | 24,240 | |
| Oct 28 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 110.00 | 2,000 | 220,007 | 32,244 | 34.2 K to 32.2 K (-5.84 %) |
| Oct 28 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 40.56 | 2,000 | 81,120 | 34,244 | 32.2 K to 34.2 K (+6.20 %) |
| Oct 23 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Option Exercise | M | 14.34 | 15,000 | 215,063 | 51,000 | |
| Oct 23 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 104.67 | 1,098 | 114,926 | 42,405 | 43.5 K to 42.4 K (-2.52 %) |
| Oct 23 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 104.03 | 13,902 | 1,446,224 | 43,503 | 57.4 K to 43.5 K (-24.22 %) |
| Oct 23 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Buy | M | 14.34 | 15,000 | 215,063 | 57,405 | 42.4 K to 57.4 K (+35.37 %) |
| Oct 09 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Option Exercise | M | 8.01 | 146,895 | 1,175,894 | 293,718 | |
| Oct 09 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 104.86 | 98,408 | 10,318,571 | 974,048 | 1.1 M to 974 K (-9.18 %) |
| Oct 09 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 104.18 | 44,387 | 4,624,282 | 1,072,456 | 1.1 M to 1.1 M (-3.97 %) |
| Oct 09 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 103.16 | 4,100 | 422,965 | 1,116,843 | 1.1 M to 1.1 M (-0.37 %) |
| Oct 09 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Buy | M | 8.01 | 146,895 | 1,175,894 | 1,120,943 | 974 K to 1.1 M (+15.08 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 8.01 | 140,625 | 1,125,703 | 281,258 | |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 107.41 | 1,400 | 150,374 | 4,429,387 | 4.4 M to 4.4 M (-0.03 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 106.60 | 29,725 | 3,168,795 | 4,430,787 | 4.5 M to 4.4 M (-0.67 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 105.71 | 109,500 | 11,574,676 | 4,460,512 | 4.6 M to 4.5 M (-2.40 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 8.01 | 140,625 | 1,125,703 | 4,570,012 | 4.4 M to 4.6 M (+3.17 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 23.76 | 31,000 | 736,405 | 73,367 | |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 106.69 | 249 | 26,566 | 120,694 | 120.9 K to 120.7 K (-0.21 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 105.91 | 1,751 | 185,443 | 120,943 | 122.7 K to 120.9 K (-1.43 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 107.47 | 200 | 21,493 | 122,694 | 122.9 K to 122.7 K (-0.16 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 106.59 | 5,395 | 575,042 | 122,894 | 128.3 K to 122.9 K (-4.21 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 105.83 | 25,405 | 2,688,715 | 128,289 | 153.7 K to 128.3 K (-16.53 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 23.76 | 31,000 | 736,405 | 153,694 | 122.7 K to 153.7 K (+25.27 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 40.56 | 2,000 | 81,120 | 26,240 | |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 106.39 | 2,000 | 212,785 | 32,244 | 34.2 K to 32.2 K (-5.84 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 40.56 | 2,000 | 81,120 | 34,244 | 32.2 K to 34.2 K (+6.20 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | M | 26.99 | 5,000 | 134,950 | 25,000 | |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 106.99 | 5,000 | 534,950 | 15,641 | 20.6 K to 15.6 K (-24.22 %) |
| Oct 03 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Buy | M | 26.99 | 5,000 | 134,950 | 20,641 | 15.6 K to 20.6 K (+31.97 %) |
| Sep 30 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 40.56 | 2,000 | 81,120 | 28,240 | |
| Sep 30 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 107.47 | 2,000 | 214,945 | 32,244 | 34.2 K to 32.2 K (-5.84 %) |
| Sep 30 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 40.56 | 2,000 | 81,120 | 34,244 | 32.2 K to 34.2 K (+6.20 %) |
| Sep 24 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Option Exercise | M | 14.34 | 5,000 | 71,688 | 66,000 | |
| Sep 24 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 107.48 | 1,801 | 193,571 | 42,405 | 44.2 K to 42.4 K (-4.07 %) |
| Sep 24 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 106.60 | 1,303 | 138,894 | 44,206 | 45.5 K to 44.2 K (-2.86 %) |
| Sep 24 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 105.76 | 1,896 | 200,522 | 45,509 | 47.4 K to 45.5 K (-4.00 %) |
| Sep 24 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Buy | M | 14.34 | 5,000 | 71,688 | 47,405 | 42.4 K to 47.4 K (+11.79 %) |
| Sep 10 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Option Exercise | M | 8.01 | 146,895 | 1,175,894 | 440,613 | |
| Sep 10 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 106.23 | 84,506 | 8,976,794 | 974,048 | 1.1 M to 974 K (-7.98 %) |
| Sep 10 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 105.67 | 62,389 | 6,592,870 | 1,058,554 | 1.1 M to 1.1 M (-5.57 %) |
| Sep 10 2014 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Buy | M | 8.01 | 146,895 | 1,175,894 | 1,120,943 | 974 K to 1.1 M (+15.08 %) |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 8.01 | 140,625 | 1,125,703 | 421,883 | |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 109.01 | 68,000 | 7,412,605 | 4,429,387 | 4.5 M to 4.4 M (-1.51 %) |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 108.30 | 72,625 | 7,865,309 | 4,497,387 | 4.6 M to 4.5 M (-1.59 %) |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 8.01 | 140,625 | 1,125,703 | 4,570,012 | 4.4 M to 4.6 M (+3.17 %) |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 23.76 | 31,000 | 736,405 | 104,367 | |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 108.98 | 767 | 83,585 | 122,694 | 123.5 K to 122.7 K (-0.62 %) |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 108.24 | 1,233 | 133,454 | 123,461 | 124.7 K to 123.5 K (-0.99 %) |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 109.02 | 13,646 | 1,487,722 | 124,694 | 138.3 K to 124.7 K (-9.86 %) |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 108.24 | 17,354 | 1,878,468 | 138,340 | 155.7 K to 138.3 K (-11.15 %) |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 23.76 | 31,000 | 736,405 | 155,694 | 124.7 K to 155.7 K (+24.86 %) |
| Aug 28 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 19.09 | 10,000 | 190,850 | 15,200 | |
| Aug 28 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 106.16 | 10,000 | 1,061,618 | 32,244 | 42.2 K to 32.2 K (-23.67 %) |
| Aug 28 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 19.09 | 10,000 | 190,850 | 42,244 | 32.2 K to 42.2 K (+31.01 %) |
| Aug 28 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 21.94 | 259 | 5,684 | 32,244 | 32 K to 32.2 K (+0.81 %) |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | M | 26.99 | 5,000 | 134,950 | 30,000 | |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 108.10 | 5,000 | 540,500 | 15,641 | 20.6 K to 15.6 K (-24.22 %) |
| Sep 04 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Buy | M | 26.99 | 5,000 | 134,950 | 20,641 | 15.6 K to 20.6 K (+31.97 %) |
| Aug 27 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 105.87 | 4,304 | 455,664 | 42,470 | 46.8 K to 42.5 K (-9.20 %) |
| Aug 18 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 40.56 | 33,556 | 1,361,031 | 55,934 | |
| Aug 18 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 95.56 | 33,556 | 3,206,611 | 49,832 | 83.4 K to 49.8 K (-40.24 %) |
| Aug 18 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 40.56 | 33,556 | 1,361,031 | 83,388 | 49.8 K to 83.4 K (+67.34 %) |
| Aug 25 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Option Exercise | M | 14.34 | 5,000 | 71,688 | 71,000 | |
| Aug 25 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 101.09 | 5,000 | 505,440 | 42,405 | 47.4 K to 42.4 K (-10.55 %) |
| Aug 25 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Buy | M | 14.34 | 5,000 | 71,688 | 47,405 | 42.4 K to 47.4 K (+11.79 %) |
| Aug 15 2014 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Gift | G | 0.00 | 4,000 | 0 | 2,154,681 | 2.2 M to 2.2 M (-0.19 %) |
| Aug 12 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 26.99 | 16,728 | 451,489 | 24,264 | |
| Aug 12 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 92.04 | 1,303 | 119,930 | 31,985 | 33.3 K to 32 K (-3.91 %) |
| Aug 12 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 91.54 | 15,425 | 1,411,951 | 33,288 | 48.7 K to 33.3 K (-31.67 %) |
| Aug 12 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 26.99 | 16,728 | 451,489 | 48,713 | 32 K to 48.7 K (+52.30 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 0.00 | 2,500 | 0 | 17,300 | |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Payment of Exercise | F | 91.50 | 1,220 | 111,630 | 31,985 | 33.2 K to 32 K (-3.67 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 0.00 | 2,500 | 0 | 33,205 | 30.7 K to 33.2 K (+8.14 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | M | 26.99 | 5,000 | 134,950 | 35,000 | |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 91.00 | 5,000 | 455,000 | 15,641 | 20.6 K to 15.6 K (-24.22 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Buy | M | 26.99 | 5,000 | 134,950 | 20,641 | 15.6 K to 20.6 K (+31.97 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 23.76 | 31,000 | 736,405 | 135,367 | |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 92.07 | 900 | 82,864 | 124,694 | 125.6 K to 124.7 K (-0.72 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 91.15 | 1,100 | 100,266 | 125,594 | 126.7 K to 125.6 K (-0.87 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 92.10 | 13,134 | 1,209,634 | 126,694 | 139.8 K to 126.7 K (-9.39 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 91.27 | 17,866 | 1,630,567 | 139,828 | 157.7 K to 139.8 K (-11.33 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 23.76 | 31,000 | 736,405 | 157,694 | 126.7 K to 157.7 K (+24.47 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 24.91 | 3,000 | 74,715 | 0 | |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 24.30 | 11,250 | 273,319 | 67,500 | |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 23.76 | 4,800 | 114,024 | 9,600 | |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 19.09 | 11,550 | 220,432 | 23,100 | |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 92.09 | 8,100 | 745,913 | 49,832 | 57.9 K to 49.8 K (-13.98 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 91.26 | 22,500 | 2,053,436 | 57,932 | 80.4 K to 57.9 K (-27.97 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 24.91 | 3,000 | 74,715 | 80,432 | 77.4 K to 80.4 K (+3.87 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 24.30 | 11,250 | 273,319 | 77,432 | 66.2 K to 77.4 K (+17.00 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 23.76 | 4,800 | 114,024 | 66,182 | 61.4 K to 66.2 K (+7.82 %) |
| Aug 05 2014 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 19.09 | 11,550 | 220,432 | 61,382 | 49.8 K to 61.4 K (+23.18 %) |
| Aug 04 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 8.01 | 140,625 | 1,125,703 | 562,508 | |
| Aug 04 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 92.10 | 41,500 | 3,822,017 | 4,429,387 | 4.5 M to 4.4 M (-0.93 %) |
| Aug 04 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 91.30 | 99,125 | 9,049,795 | 4,470,887 | 4.6 M to 4.5 M (-2.17 %) |
| Aug 04 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 8.01 | 140,625 | 1,125,703 | 4,570,012 | 4.4 M to 4.6 M (+3.17 %) |
| Jul 30 2014 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Option Exercise | M | 26.62 | 45,000 | 1,197,675 | 0 | |
| Jul 30 2014 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Sell | S | 90.56 | 45,000 | 4,075,403 | 0 | 45 K to 0 (-100.00 %) |
| Jul 30 2014 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Buy | M | 26.62 | 45,000 | 1,197,675 | 45,000 | 0 to 45 K |
| Jul 23 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Option Exercise | M | 14.34 | 5,000 | 71,688 | 76,000 | |
| Jul 23 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 90.16 | 1,196 | 107,827 | 42,405 | 43.6 K to 42.4 K (-2.74 %) |
| Jul 23 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 89.52 | 3,804 | 340,515 | 43,601 | 47.4 K to 43.6 K (-8.02 %) |
| Jul 23 2014 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Buy | M | 14.34 | 5,000 | 71,688 | 47,405 | 42.4 K to 47.4 K (+11.79 %) |
| Jul 10 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 26.99 | 16,728 | 451,489 | 40,992 | |
| Jul 10 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 86.45 | 16,728 | 1,446,074 | 30,705 | 47.4 K to 30.7 K (-35.27 %) |
| Jul 10 2014 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 26.99 | 16,728 | 451,489 | 47,433 | 30.7 K to 47.4 K (+54.48 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 23.76 | 1,633 | 38,792 | 166,367 | |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 23.60 | 29,367 | 693,061 | 5,000 | |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 85.04 | 1,300 | 110,557 | 126,694 | 128 K to 126.7 K (-1.02 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 83.94 | 700 | 58,757 | 127,994 | 128.7 K to 128 K (-0.54 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 85.37 | 800 | 68,298 | 128,694 | 129.5 K to 128.7 K (-0.62 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 84.97 | 7,400 | 628,773 | 129,494 | 136.9 K to 129.5 K (-5.41 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 83.76 | 22,800 | 1,909,692 | 136,894 | 159.7 K to 136.9 K (-14.28 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 23.76 | 1,633 | 38,792 | 159,694 | 158.1 K to 159.7 K (+1.03 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 23.60 | 29,367 | 693,061 | 158,061 | 128.7 K to 158.1 K (+22.82 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 8.01 | 140,625 | 1,125,703 | 703,133 | |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 85.40 | 18,100 | 1,545,678 | 4,429,387 | 4.4 M to 4.4 M (-0.41 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 85.01 | 92,300 | 7,846,728 | 4,447,487 | 4.5 M to 4.4 M (-2.03 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 83.96 | 30,225 | 2,537,555 | 4,539,787 | 4.6 M to 4.5 M (-0.66 %) |
| Jul 03 2014 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 8.01 | 140,625 | 1,125,703 | 4,570,012 | 4.4 M to 4.6 M (+3.17 %) |
| Jul 02 2014 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Option Exercise | A | 0.00 | 1,011 | 0 | 17,355 | |
| Jul 02 2014 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Option Exercise | A | 0.00 | 791 | 0 | 23,895 | |
| Jul 02 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | M | 26.99 | 5,000 | 134,950 | 40,000 | |
| Jul 02 2014 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 83.65 | 5,000 | 418,250 | 15,641 | 20.6 K to 15.6 K (-24.22 %) |